CD19 and acute lymphoblastic leukemia: Finally, a third trial (107) for R/R ALL treated 14 additional patients with LD consisting of 3 days Flu 25 mg/m2 and 1 day of Cy 900 mg/m2 followed by an anti-CD19 CD28-based CAR-T, achieving an 85% Minimal Residual Disease (MRD)-negative CRR.